95.29
Schlusskurs vom Vortag:
$102.05
Offen:
$101.95
24-Stunden-Volumen:
63,059
Relative Volume:
1.21
Marktkapitalisierung:
$587.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.12M
KGV:
-41.43
EPS:
-2.3
Netto-Cashflow:
$-6.82M
1W Leistung:
-3.28%
1M Leistung:
+93.60%
6M Leistung:
+154.17%
1J Leistung:
+1,668%
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Firmenname
Monopar Therapeutics Inc
Sektor
Branche
Telefon
(847) 388-0349
Adresse
1000 SKOKIE BLVD SUITE 350, WILMETTE
Vergleichen Sie MNPR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
MNPR
Monopar Therapeutics Inc
|
95.29 | 629.64M | 0 | -7.12M | -6.82M | -2.30 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-09-09 | Eingeleitet | BTIG Research | Buy |
2025-09-03 | Eingeleitet | Oppenheimer | Outperform |
2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
2025-08-26 | Fortgesetzt | H.C. Wainwright | Buy |
2025-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
2025-06-23 | Eingeleitet | Chardan Capital Markets | Buy |
2025-03-19 | Fortgesetzt | Piper Sandler | Overweight |
2025-01-10 | Eingeleitet | Piper Sandler | Overweight |
2024-10-11 | Eingeleitet | Rodman & Renshaw | Buy |
2021-01-28 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Monopar Therapeutics Inc Aktie (MNPR) Neueste Nachrichten
Key metrics from Monopar Therapeutics Inc.’s quarterly dataTrade Analysis Summary & Safe Capital Growth Trade Ideas - newser.com
Is Monopar Therapeutics Inc. forming a reversal patternQuarterly Portfolio Review & Daily Profit Focused Screening - newser.com
Monopar Therapeutics (NASDAQ:MNPR) Trading Up 16.3% After Analyst Upgrade - Defense World
Is Monopar Therapeutics Inc. stock safe for conservative investorsWeekly Trade Recap & Free High Return Stock Watch Alerts - newser.com
Multi factor analysis applied to Monopar Therapeutics Inc.2025 Macro Impact & Weekly Chart Analysis and Guides - newser.com
Will Monopar Therapeutics Inc. stock recover faster than peersJuly 2025 Snapshot & Weekly Watchlist for Hot Stocks - newser.com
MNPR: Barclays Initiates Coverage with Overweight Rating | MNPR Stock News - GuruFocus
This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Monopar Therapeutics initiated with an Overweight at Barclays - TipRanks
Heatmap analysis for Monopar Therapeutics Inc. and competitors2025 Key Lessons & Daily Volume Surge Trade Alerts - newser.com
Real time social sentiment graph for Monopar Therapeutics Inc.Weekly Trade Recap & Free Community Consensus Stock Picks - newser.com
Monopar Therapeutics (NASDAQ:MNPR) Raised to Strong-Buy at Jones Trading - Defense World
Monopar Therapeutics (NASDAQ:MNPR) Stock Price Down 12.3%Here's What Happened - MarketBeat
Monopar Therapeutics (NASDAQ:MNPR) Upgraded to "Strong-Buy" at Jones Trading - MarketBeat
Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted (NASDAQ:MNPR) - Seeking Alpha
Institutional scanner results for Monopar Therapeutics Inc.2025 Momentum Check & High Win Rate Trade Alerts - newser.com
Monopar Therapeutics' (MNPR) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Monopar Therapeutics Inc.: Promising Prospects with ALXN1840 Acquisition and Wilson’s Disease Market Potential - TipRanks
What analysts say about Monopar Therapeutics Inc stockProtective Put Strategies & Low Risk Investment Trading - earlytimes.in
How Monopar Therapeutics Inc. (1IY0) stock reacts to monetary easingJuly 2025 Breakouts & Precise Trade Entry Recommendations - newser.com
Raymond James Maintains Monopar Therapeutics (MNPR) Strong Buy Recommendation - Nasdaq
MNPR: Raymond James Raises Price Target to $142, Maintains Stron - GuruFocus
Monopar Therapeutics (NASDAQ:MNPR) Hits New 1-Year HighTime to Buy? - MarketBeat
How to integrate Monopar Therapeutics Inc. into portfolio analysis toolsWatch List & Fast Gaining Stock Strategy Reports - newser.com
Historical volatility pattern of Monopar Therapeutics Inc. visualizedTrade Entry Summary & Entry Point Strategy Guides - newser.com
Will Monopar Therapeutics Inc. (1IY0) stock beat Nasdaq index returnsTrade Risk Summary & Long-Term Safe Investment Ideas - newser.com
Risk adjusted return profile for Monopar Therapeutics Inc. analyzedJuly 2025 Big Picture & High Return Stock Watch Alerts - newser.com
Can trapped investors hope for a rebound in Monopar Therapeutics Inc.Watch List & Fast Entry Momentum Alerts - newser.com
Is Monopar Therapeutics Inc. (1IY0) stock overpriced at current multiplesJuly 2025 Recap & Entry Point Confirmation Signals - newser.com
Using portfolio simulators with Monopar Therapeutics Inc. includedJuly 2025 Retail & Reliable Price Breakout Alerts - newser.com
Analyzing Monopar Therapeutics Inc. with risk reward ratio chartsGlobal Markets & Community Shared Stock Ideas - newser.com
Can volume confirm reversal in Monopar Therapeutics Inc.July 2025 Macro Moves & Reliable Price Breakout Signals - newser.com
Oppenheimer Maintains Monopar Therapeutics (MNPR) Outperform Recommendation - Nasdaq
Oppenheimer Raises Price Target for Monopar Therapeutics (MNPR) - GuruFocus
Finanzdaten der Monopar Therapeutics Inc-Aktie (MNPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Monopar Therapeutics Inc-Aktie (MNPR) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Tsuchimoto Kim R | Director |
Jul 14 '25 |
Sale |
40.00 |
8,904 |
356,171 |
11,486 |
STARR CHRISTOPHER M | Director |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
5,173 |
Robinson Chandler | Chief Executive Officer |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
73,472 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):